Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CRISPR Therapeutics AG is a clinical-stage biotechnology company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. The company operates within the biotechnology and life sciences industries, with a primary emphasis on gene editing therapies for serious diseases. Its core revenue drivers to date are collaboration and license revenues, milestone payments, and, more recently, product-related revenue tied to its first commercial therapy.
The company is best known for the development of CASGEVY (formerly exa-cel), a CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed in partnership with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, one of the pioneers of CRISPR/Cas9 technology, and has since evolved from a research-focused organization into a late-stage clinical and early commercial biotechnology company following regulatory approvals in multiple major markets.
Business Operations
CRISPR Therapeutics operates primarily through a single reporting segment focused on gene editing therapeutics, encompassing research, development, and commercialization activities. The company’s pipeline includes wholly owned and partnered programs across hemoglobinopathies, oncology, regenerative medicine, and autoimmune diseases. Revenue generation has historically come from research collaborations and milestone payments, with product revenue emerging following the approval of CASGEVY.
The company controls a broad portfolio of CRISPR/Cas9 intellectual property and development capabilities, including in-house research, preclinical development, and clinical trial management. A central operational partnership is its global collaboration with Vertex Pharmaceuticals Incorporated, which covers the development, manufacturing, and commercialization of CASGEVY, with profits and costs shared under a joint agreement. CRISPR Therapeutics also maintains subsidiaries to support regional operations and clinical development activities.
Strategic Position & Investments
Strategically, CRISPR Therapeutics is focused on advancing its next-generation gene editing pipeline while expanding the commercial footprint of CASGEVY. Growth initiatives include progressing wholly owned programs such as CTX310 and CTX320 for cardiovascular disease, and CTX131 for oncology, which leverage in vivo and ex vivo gene-editing approaches.
The company has made significant long-term investments in manufacturing capabilities, clinical infrastructure, and intellectual property to support scalable gene-editing therapies. Its partnership with Vertex Pharmaceuticals Incorporated represents its most significant strategic collaboration, while internal R&D investment remains concentrated on emerging applications of CRISPR technology, including regenerative medicine and immuno-oncology. No major acquisitions have been disclosed beyond strategic collaborations and licensing arrangements.
Geographic Footprint
CRISPR Therapeutics is headquartered in Zug, Switzerland, with major operational and research activities in the United States, particularly Massachusetts and California. These U.S. locations support research, clinical development, and corporate functions.
The company has a growing international presence through clinical trials, regulatory approvals, and commercialization activities across North America, Europe, and select other global markets. Through its partnership with Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics has indirect commercial reach in additional regions, including parts of Asia-Pacific and the Middle East, where approved therapies are being introduced or evaluated.
Leadership & Governance
CRISPR Therapeutics is led by a management team with extensive experience in biotechnology, pharmaceuticals, and clinical development. The company emphasizes a leadership philosophy centered on scientific rigor, disciplined clinical execution, and responsible commercialization of gene-editing technologies.
Key executives include:
- Samarth Kulkarni – Chief Executive Officer
- Emmanuelle Charpentier – Founder
- Brendan Bulik-Sullivan – Chief Operating Officer
- Sarah Boyce – Chief Financial Officer
- Julian Levitt – Chief Business Officer
- Joern Aldag – Chairman of the Board
The board and executive leadership oversee governance, strategic direction, and compliance, with a stated focus on long-term value creation and ethical application of genome-editing science.